TY - JOUR
AU1 - CRYSTAL, EUGENE
AU2 - OVSYSHCHER, I. ELI
AB -  Introduction Cardiac pacing and implantable cardioverter defibrillator (ICD) therapies are guided today by evidence levels of the efficacy of therapy in the improvement of brady‐ and tachycardia related morbidity and mortality. The data regarding such superiority is derived from many randomized trials (evidence level A), a limited number of randomized and/or carefully conducted nonrandomized studies (evidence level B), or from expert consensus (evidence level C). The formal indications for pacing and ICD therapies are then graded in written guidelines into Class I (the procedure is helpful and effective), Class II (conflicting evidence of efficacy), and Class III (procedure is not useful). The sections Selection of Pacemaker Device (pages 15–19 of the full version ) and Selection of ICD Generators (pages 28–29 of the full version ) of the most recent American Heart Association (AHA)/American College of Cardiology (ACC)/North American Society of Pacing and Electrophysiology (NASPE) guidelines dealing with a selection of implantable pacing/ICD devices provides the physician with only general, evocative, and not evidence grounded recommendations for the use of specific devices. It has become clear that the body of evidence provided by numerous studies is now sufficient that appropriate modification of the current guidelines should be considered 
TI - Implantable Device Selection:
JF - Pacing and Clinical Electrophysiology
DO - 10.1046/j.1460-9592.2003.t01-1-00271.x
DA - 2003-09-01
UR - https://www.deepdyve.com/lp/wiley/implantable-device-selection-k3fjvYKfci
SP - 1793
VL - 26
IS - 9
DP - DeepDyve
ER -